PMID- 30518618
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Dec 5
TI  - Incretin based drugs and risk of cholangiocarcinoma among patients with type 2
      diabetes: population based cohort study.
PG  - k4880
LID - 10.1136/bmj.k4880 [doi]
AB  - OBJECTIVE: To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors 
      and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an
      increased risk of cholangiocarcinoma in adults with type 2 diabetes. DESIGN:
      Population based cohort study. SETTING: General practices contributing data to
      the UK Clinical Practice Research Datalink. PARTICIPANTS: 154 162 adults newly
      treated with antidiabetic drugs between 1 January 2007 and 31 March 2017,
      followed until 31 March 2018. MAIN OUTCOME MEASURES: Use of DPP-4 inhibitors and 
      GLP-1 receptor agonists was modelled as a time varying variable and compared with
      use of other second or third line antidiabetic drugs. All exposures were lagged
      by one year to account for cancer latency and to minimise reverse causality. Cox 
      proportional hazards models were used to estimate hazard ratios and 95%
      confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 
      inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance 
      analysis was conducted using the World Health Organization's global individual
      case safety report database, VigiBase, to estimate reporting odds ratios of
      cholangiocarcinoma. RESULTS: During 614 274 person years of follow-up, 105
      incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years).
      Use of DPP-4 inhibitors was associated with a 77% increased hazard of
      cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use
      of GLP-1 receptor agonists was associated with an increased hazard with a wide
      confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance
      analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both
      associated with increased reporting odds ratios for cholangiocarcinoma, compared 
      with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95
      to 7.58, respectively). CONCLUSION: Compared with use of other second or third
      line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor
      agonists, might be associated with an increased risk of cholangiocarcinoma in
      adults with type 2 diabetes.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Abrahami, Devin
AU  - Abrahami D
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, QC, Canada.
FAU - Douros, Antonios
AU  - Douros A
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, QC, Canada.
AD  - Institute of Clinical Pharmacology and Toxicology, Charite University Medicine
      Berlin, Berlin, Germany.
FAU - Yin, Hui
AU  - Yin H
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
FAU - Yu, Oriana Hy
AU  - Yu OH
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
AD  - Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada.
FAU - Faillie, Jean-Luc
AU  - Faillie JL
AD  - Department of Medical Pharmacology and Toxicology, CHU Montpellier; Laboratory of
      Biostatistics, Epidemiology and Public Health, University of Montpellier,
      Montpellier, France.
FAU - Montastruc, Francois
AU  - Montastruc F
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and 
      Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital,
      Faculty of Medicine, University of Toulouse, France.
FAU - Platt, Robert W
AU  - Platt RW
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, QC, Canada.
FAU - Bouganim, Nathaniel
AU  - Bouganim N
AD  - Department of Oncology, McGill University Health Centre, Montreal, QC, Canada.
AD  - Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
FAU - Azoulay, Laurent
AU  - Azoulay L
AUID- ORCID: http://orcid.org/0000-0001-5162-3556
AD  - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 
      3755 Cote Sainte-Catherine Road, H425.1, Montreal, QC, H3T 1E2, Canada
      laurent.azoulay@mcgill.ca.
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, QC, Canada.
AD  - Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20181205
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
PMC - PMC6278586
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare: this study was funded by the
      Canadian Institutes of Health Research. RWP received consulting fees for work
      unrelated to this project from Amgen, Eli Lilly, Merck, and Pfizer. All other
      authors have no conflicts to disclose, and have no financial relationships with
      any organisations that might have an interest in the submitted work in the
      previous three years; no other relationships or activities that could appear to
      have influenced the submitted work.
EDAT- 2018/12/07 06:00
MHDA- 2018/12/07 06:00
CRDT- 2018/12/07 06:00
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2018/12/07 06:00 [medline]
AID - 10.1136/bmj.k4880 [doi]
PST - epublish
SO  - BMJ. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880.

PMID- 30504130
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Nov 30
TI  - Type 2 diabetes: 5000 patients to test feasibility of "remission service".
PG  - k5114
LID - 10.1136/bmj.k5114 [doi]
FAU - Feinmann, Jane
AU  - Feinmann J
AD  - London.
LA  - eng
PT  - Journal Article
DEP - 20181130
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2018/12/07 06:00
MHDA- 2018/12/07 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2018/12/07 06:00 [medline]
AID - 10.1136/bmj.k5114 [doi]
PST - epublish
SO  - BMJ. 2018 Nov 30;363:k5114. doi: 10.1136/bmj.k5114.

PMID- 30511764
OWN - NLM
STAT- Publisher
LR  - 20181215
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Dec 4
TI  - Prospective memory slips are associated with forgetting to take glucose-lowering 
      therapies among adults with diabetes: results from the second Diabetes MILES -
      Australia (MILES-2) survey.
LID - 10.1111/dme.13873 [doi]
AB  - AIMS: Prospective memory has been long considered a fundamental cognitive ability
      for optimal medication taking, but the role of prospective memory errors (termed 
      'slips') in diabetes self-care is unclear. Our aim was to examine associations
      between prospective memory and medication taking in adults with Type 1 and Type 2
      diabetes mellitus. METHODS: Some 901 adults with Type 1 diabetes and 927 with
      Type 2 diabetes completed a cross-sectional survey focused on the psychological
      and behavioural aspects of living with diabetes. Respondents reported whether
      they had forgotten to take their diabetes medication over the previous 14 days.
      RESULTS: Twenty-four per cent (n = 220) of adults with Type 1 diabetes and 23% (n
      = 211) with Type 2 diabetes reported that they had forgotten their medication at 
      least once over the previous 14 days. This was associated with more prospective
      memory slips in adults with Type 1 diabetes [odds ratio (OR) 1.09, 95% confidence
      interval (CI) 1.05 to 1.13; P < 0.001] and Type 2 diabetes (OR 1.10, 95% CI 1.05 
      to 1.15; P < 0.001); and with younger age (both groups), insulin pump use (Type 1
      diabetes), insulin treatment (Type 2 diabetes), less frequent blood glucose
      checks (Type 1 diabetes) and higher HbA1c (Type 1 diabetes). CONCLUSIONS: These
      findings suggest that forgetting medication is relatively common among adults
      with Type 1 or Type 2 diabetes, and provide preliminary evidence for its
      relationship with self-reported prospective memory slips.
CI  - (c) 2018 Diabetes UK.
FAU - Trawley, S
AU  - Trawley S
AUID- ORCID: http://orcid.org/0000-0002-0917-730X
AD  - The Cairnmillar Institute, Melbourne, Victoria, Australia.
AD  - School of Psychology, Deakin University, Geelong, Victoria, Australia.
AD  - The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria,
      Melbourne, Victoria, Australia.
FAU - Baptista, S
AU  - Baptista S
AD  - School of Psychology, Deakin University, Geelong, Victoria, Australia.
AD  - The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria,
      Melbourne, Victoria, Australia.
AD  - Non Communicable Disease Unit, Melbourne School of Population and Global Health, 
      The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Pouwer, F
AU  - Pouwer F
AD  - School of Psychology, Deakin University, Geelong, Victoria, Australia.
AD  - STENO Diabeter Center Odense, Odense University Hospital, Odense, Denmark.
FAU - Speight, J
AU  - Speight J
AUID- ORCID: http://orcid.org/0000-0002-1204-6896
AD  - School of Psychology, Deakin University, Geelong, Victoria, Australia.
AD  - The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria,
      Melbourne, Victoria, Australia.
AD  - Department of Psychology, University of Southern Denmark, Odense, Denmark.
AD  - AHP Research, Hornchurch, UK.
LA  - eng
GR  - Sanofi ANZ
PT  - Journal Article
DEP - 20181204
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/12/05 06:00
MHDA- 2018/12/05 06:00
CRDT- 2018/12/05 06:00
PHST- 2018/11/29 00:00 [accepted]
PHST- 2018/12/05 06:00 [pubmed]
PHST- 2018/12/05 06:00 [medline]
PHST- 2018/12/05 06:00 [entrez]
AID - 10.1111/dme.13873 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Dec 4. doi: 10.1111/dme.13873.

PMID- 30521046
OWN - NLM
STAT- Publisher
LR  - 20181206
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Dec 5
TI  - Exposure to gestational diabetes is a stronger predictor of dysmetabolic traits
      in children than size at birth.
LID - 10.1210/jc.2018-02044 [doi]
AB  - Context and Objective: Being born small or large for gestational age and
      intrauterine exposure to gestational diabetes (GDM) increase the risk of type 2
      diabetes (T2D) in the offspring, however, the potential combined deleterious
      effects of size at birth and GDM exposure remains unknown. We aimed to examine
      the independent effect of size at birth as well as the influence of GDM exposure 
      in utero on cardio-metabolic traits, body composition, and puberty status in
      children. Design, Participants and Methods: This study is a longitudinal birth
      cohort study. We used clinical data from 490 offspring of mothers with GDM and
      527 control offspring aged 9-16 years, born singleton at term from the Danish
      National Birth Cohort with available birth weight data. Results: We found no
      evidence of a U-shaped association between size at birth (expressed as birth
      weight, sex and gestational age adjusted z-score) and cardio-metabolic traits.
      Body size in childhood and adolescence reflected size at birth, but was not
      reflected in any metabolic outcome. No synergistic adverse effect of being born
      small or large for gestational age and being exposed to GDM was shown. However,
      GDM was associated with an adverse metabolic profile and earlier onset of female 
      puberty in childhood and adolescence independently of size at birth. Conclusion: 
      In childhood and adolescence, GDM is a stronger predictor of dysmetabolic traits 
      than size at birth. The combination of being born small or large and being
      exposed to GDM does not exacerbate the metabolic profile in the offspring.
FAU - Kampmann, Freja Bach
AU  - Kampmann FB
AD  - Division for Diet, Disease Prevention and Toxicology, National Food Institute,
      Technical University of Denmark, Kgs. Lyngby, Denmark.
AD  - Department of Endocrinology, Diabetes and Bone-metabolic Research Unit,
      Rigshospitalet, Copenhagen Denmark.
AD  - The Danish Diabetes Academy, Odense, Denmark.
FAU - Thuesen, Anne Cathrine Baun
AU  - Thuesen ACB
AD  - Department of Endocrinology, Diabetes and Bone-metabolic Research Unit,
      Rigshospitalet, Copenhagen Denmark.
FAU - Hjort, Line
AU  - Hjort L
AD  - Department of Endocrinology, Diabetes and Bone-metabolic Research Unit,
      Rigshospitalet, Copenhagen Denmark.
FAU - Olsen, Sjurdur Frodi
AU  - Olsen SF
AD  - Centre for Foetal Programming, Department of Epidemiology Research, Statens Serum
      Institut, Copenhagen, Denmark.
FAU - Pires, Sara Monteiro
AU  - Pires SM
AD  - Division for Diet, Disease Prevention and Toxicology, National Food Institute,
      Technical University of Denmark, Kgs. Lyngby, Denmark.
FAU - Tetens, Inge
AU  - Tetens I
AD  - Vitality - Centre for Good Older Lives, Department of Nutrition, Sports &
      Exercise, University of Copenhagen, Denmark.
FAU - Grunnet, Louise Groth
AU  - Grunnet LG
AD  - Department of Endocrinology, Diabetes and Bone-metabolic Research Unit,
      Rigshospitalet, Copenhagen Denmark.
AD  - The Danish Diabetes Academy, Odense, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20181205
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/12/07 06:00
MHDA- 2018/12/07 06:00
CRDT- 2018/12/07 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2018/12/07 06:00 [entrez]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2018/12/07 06:00 [medline]
AID - 5230930 [pii]
AID - 10.1210/jc.2018-02044 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Dec 5. pii: 5230930. doi: 10.1210/jc.2018-02044.

PMID- 30517677
OWN - NLM
STAT- Publisher
LR  - 20181205
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Dec 4
TI  - BMI change during puberty is an important determinant of adult type 2 diabetes
      risk in men.
LID - 10.1210/jc.2018-01339 [doi]
AB  - Objective: The aim of this study was to determine the role of change in body mass
      index (BMI) during puberty, independent of childhood overweight, for the risk of 
      adult type 2 diabetes in men. Study design, population and outcome: We included
      36,176 men who had weight and height measured at age 8 (childhood) and 20 (young 
      adult age) available from the BMI Epidemiology Study (BEST) and the Conscription 
      register. Information on type 2 diabetes (n=1,777) was retrieved from the Swedish
      National Patient Register. Hazard ratios and 95% Confidence Intervals were
      estimated by Cox regressions including birth year and country of birth as
      covariates. Because the assumption of proportional hazards was violated for the
      association between BMI change during puberty and type 2 diabetes, we split the
      follow-up time into early (</=55.7 years) and late (>55.7 years). Results: Both
      childhood overweight and a high BMI increase during puberty associated with risk 
      of adult type 2 diabetes. Men with childhood overweight that normalized during
      puberty did not have a significantly increased risk of type 2 diabetes (Early
      type 2 diabetes 1.28[0.89; 1.82]; Late type 2 diabetes 1.35[0.97; 1.87]). Men who
      developed overweight during puberty (Early 4.67[3.90; 5.58]; Late 2.85[2.25;
      3.61]) and men overweight at both childhood and young adult age (Early 4.82[3.84;
      6.05]; Late 3.04[2.27; 4.06]) had substantially increased risk of type 2 diabetes
      compared with men who were never overweight. Conclusion: BMI change during
      puberty is an important, and childhood BMI a modest, independent determinant of
      adult type 2 diabetes risk in men.
FAU - Ohlsson, Claes
AU  - Ohlsson C
AD  - Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska
      Academy at University of Gothenburg, Gothenburg, Sweden.
FAU - Bygdell, Maria
AU  - Bygdell M
AD  - Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska
      Academy at University of Gothenburg, Gothenburg, Sweden.
FAU - Nethander, Maria
AU  - Nethander M
AD  - Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska
      Academy at University of Gothenburg, Gothenburg, Sweden.
AD  - Bioinformatics Core Facility, the Sahlgrenska Academy at University of
      Gothenburg, Gothenburg, Sweden.
FAU - Rosengren, Annika
AU  - Rosengren A
AD  - Department of Molecular and Clinical Medicine, the Sahlgrenska Academy,
      University of Gothenburg, Gothenburg, Sweden.
FAU - Kindblom, Jenny M
AU  - Kindblom JM
AD  - Centre for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska
      Academy at University of Gothenburg, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20181204
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/12/06 06:00
MHDA- 2018/12/06 06:00
CRDT- 2018/12/06 06:00
PHST- 2018/06/20 00:00 [received]
PHST- 2018/11/29 00:00 [accepted]
PHST- 2018/12/06 06:00 [entrez]
PHST- 2018/12/06 06:00 [pubmed]
PHST- 2018/12/06 06:00 [medline]
AID - 5224761 [pii]
AID - 10.1210/jc.2018-01339 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Dec 4. pii: 5224761. doi: 10.1210/jc.2018-01339.

PMID- 30517676
OWN - NLM
STAT- Publisher
LR  - 20181205
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Dec 3
TI  - Adipose tissue exosomal proteomic profile reveals a role on placenta glucose
      metabolism in gestational diabetes mellitus.
LID - 10.1210/jc.2018-01599 [doi]
AB  - Context: Molecules produced by adipose tissue (AT) function as an endocrine link 
      between maternal AT and fetal growth by regulating placental function in normal
      and gestational diabetes mellitus (GDM). Objective: We hypothesised that
      AT-derived exosomes from women with GDM carry a specific set of proteins that
      influences glucose metabolism in placenta. Design: Exosomes were isolated from
      omental AT-conditioned media from pregnant women with normal glucose tolerance
      (exo-NGT, n=65) and women with GDM (exo-GDM, n=82). SWATH mass spectrometry (MS) 
      was used to construct a small ion library from AT and exosomal proteins followed 
      by ingenuity pathway analysis (IPA) to determine canonical pathways and
      biofunctions. The effect of exosomes on human placental cells was determined
      using a Human Glucose Metabolism RT2 Profiler PCR Array. Results: The number of
      exosomes (vesicles/mug-tissue/24h) was significantly (1.7-fold) higher in GDM
      compared to NGT, and the number of exosomes positively correlated with
      birthweight Z score. IPA of the exosomal proteins revealed differential
      expression of the proteins targeting sirtuin (sirt) signalling pathway, oxidative
      phosphorylation (OXPHOS) and mechanistic target of rapamycin (mTOR) signalling
      pathways in GDM compared to NGT. Exo-GDM increased the expression of genes
      associated with glycolysis and gluconeogenesis in placental cells compared to the
      effect of exo-NGT. Conclusions: Our findings are consistent with the possibility 
      that AT exosomes play an important role in mediating the changes in placental
      function in GDM, which may be responsible for some of the adverse consequences in
      this pregnancy complication, such as fetal overgrowth.
FAU - Jayabalan, Nanthini
AU  - Jayabalan N
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
FAU - Lai, Andrew
AU  - Lai A
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
FAU - Ormazabal, Valeska
AU  - Ormazabal V
AD  - Faculty of Biological Sciences, University of Concepcion, Concepcion, Chile.
FAU - Adam, Stefanie
AU  - Adam S
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
FAU - Guanzon, Dominic
AU  - Guanzon D
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
FAU - Palma, Carlos
AU  - Palma C
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
FAU - Scholz-Romero, Katherin
AU  - Scholz-Romero K
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
AD  - Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy,
      University of Concepcion, Concepcion, Chile.
FAU - Lim, Ratana
AU  - Lim R
AD  - Obstetrics, Nutrition and Endocrinology Group, Department of Obstetrics and
      Gynaecology, University of Melbourne, Victoria, Australia.
AD  - Mercy Perinatal Research Centre, Mercy Hospital for Women, Victoria, Australia.
FAU - Jansson, Thomas
AU  - Jansson T
AD  - Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical 
      Campus, Aurora, CO, USA.
FAU - McIntyre, Harold David
AU  - McIntyre HD
AD  - Mater Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD,
      Australia.
FAU - Lappas, Martha
AU  - Lappas M
AD  - Obstetrics, Nutrition and Endocrinology Group, Department of Obstetrics and
      Gynaecology, University of Melbourne, Victoria, Australia.
AD  - Mercy Perinatal Research Centre, Mercy Hospital for Women, Victoria, Australia.
FAU - Salomon, Carlos
AU  - Salomon C
AD  - Exosome Biology Laboratory, Centre for Clinical Diagnostics, University of
      Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, The
      University of Queensland, Brisbane QLD, Australia.
AD  - Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy,
      University of Concepcion, Concepcion, Chile.
LA  - eng
PT  - Journal Article
DEP - 20181203
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/12/06 06:00
MHDA- 2018/12/06 06:00
CRDT- 2018/12/06 06:00
PHST- 2018/07/24 00:00 [received]
PHST- 2018/11/28 00:00 [accepted]
PHST- 2018/12/06 06:00 [entrez]
PHST- 2018/12/06 06:00 [pubmed]
PHST- 2018/12/06 06:00 [medline]
AID - 5224750 [pii]
AID - 10.1210/jc.2018-01599 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Dec 3. pii: 5224750. doi: 10.1210/jc.2018-01599.

PMID- 30500906
OWN - NLM
STAT- In-Data-Review
LR  - 20190116
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 104
IP  - 3
DP  - 2019 Mar 1
TI  - Body-Weight Fluctuation and Incident Diabetes Mellitus, Cardiovascular Disease,
      and Mortality: A 16-Year Prospective Cohort Study.
PG  - 639-646
LID - 10.1210/jc.2018-01239 [doi]
AB  - Context: Body-weight fluctuation (weight cycling) has been found to be associated
      with higher mortality and cardiovascular events in patients with coronary artery 
      disease. However, there are very limited data regarding the relationship between 
      body-weight fluctuation and health-related outcomes in the general population.
      Methods: We examined whether body-weight fluctuation can associate incident
      diabetes mellitus and cardiovascular events, and mortality in a Korean population
      from the Korean Genome and Epidemiology Study. The intraindividual fluctuations
      of body weight were calculated by average successive variability (ASV);
      health-related outcomes were collected every 2 years for 16 years in 3,678
      participants. Results: Participants with a high ASV of body weight were more
      obese and had higher blood pressure and HbA1c levels at baseline than those with 
      a low ASV of body weight. A 1-unit increase in ASV of body weight was associated 
      with increase in mortality (HR, 1.46; 95% CI, 1.32 to 1.62; P < 0.001). However, 
      the association between the ASV of body weight and incident diabetes mellitus
      seemed to be influenced by baseline body mass index (BMI): negative effect in
      subjects with BMI <25 kg/m2 (HR, 1.36; 95% CI, 1.11 to 1.65; P = 0.003) and
      protective effect in those with BMI >/=25 kg/m2 (HR, 0.76; 95% CI, 0.60 to 0.95; 
      P = 0.014). There was no association between the ASV of body weight and
      cardiovascular event. Conclusion: Body-weight fluctuation was associated with
      mortality. In addition, the effect of body-weight fluctuation on incident
      diabetes mellitus depended on the presence of obesity at baseline.
FAU - Oh, Tae Jung
AU  - Oh TJ
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - Moon, Jae Hoon
AU  - Moon JH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - Choi, Sung Hee
AU  - Choi SH
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - Lim, Soo
AU  - Lim S
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - Park, Kyong Soo
AU  - Park KS
AD  - Seoul National University College of Medicine, Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul,
      Korea.
FAU - Cho, Nam H
AU  - Cho NH
AD  - Department of Preventive Medicine, Ajou University School of Medicine, Suwon,
      Korea.
FAU - Jang, Hak Chul
AU  - Jang HC
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
AD  - Seoul National University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/12/01 06:00
MHDA- 2018/12/01 06:00
CRDT- 2018/12/01 06:00
PHST- 2018/06/05 00:00 [received]
PHST- 2018/10/09 00:00 [accepted]
PHST- 2018/12/01 06:00 [pubmed]
PHST- 2018/12/01 06:00 [medline]
PHST- 2018/12/01 06:00 [entrez]
AID - 5214055 [pii]
AID - 10.1210/jc.2018-01239 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2019 Mar 1;104(3):639-646. doi: 10.1210/jc.2018-01239.